- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01696643
Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Phase 3 Study to Evaluate the Long-Term Safety and Tolerability of CB-5945 for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Is taking a stable daily dose of opioids of ≥30-mg morphine-equivalent total daily dose (METDD) for chronic non-cancer pain
- Has constipation that is caused by the chronic use of opioids
- Is willing to use only the study-provided laxative(s) and to discontinue use of all other laxatives, enemas, stool softeners, and other medications to treat constipation (for example, lubiprostone) during the study period (from Screening until the last study assessment).
- Is able and willing to refrain from facilitating defecation via manual maneuvers (for example, digital evacuation or support of the pelvic floor) during the study period (from Screening to the last study assessment)
Exclusion Criteria:
- Has gastrointestinal (GI) or pelvic disorders known to affect bowel transit (for example, obstruction) or contribute to bowel dysfunction
- Has evidence of intestinal obstruction
- Has a history of rectal bleeding not due to hemorrhoids or fissures
- Has an active malignancy of any type (participants with a history of successfully treated malignancy >5 years before the scheduled administration of study medication and participants with treated basal or squamous cell cancer may be enrolled)
- Is taking antispasmodics (for example, dicyclomine), antidiarrheals (for example, loperamide), prokinetics (for example, metoclopramide), or locally acting chloride channel activators (for example, lubiprostone)
- Is taking non-opioid medications known to cause constipation (for example, iron sulfate therapy or tricyclic antidepressants)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CB-5945
0.25 milligrams (mg) CB-5945, administered orally, twice daily (BID) for 52 weeks
|
Other Names:
|
Placebo Comparator: Placebo
Placebo, administered orally, BID for 52 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time Frame: Baseline through Week 56
|
A TEAE was defined as any adverse event (AE) that occurred from the time of first dose of the study drug through the last study evaluation or pre-existing AEs that were aggravated in severity or frequency during the dosing period.
The percentages of participants with at least 1 TEAE, with at least 1 drug-related TEAE (drug-related included "possibly related" or "related" as deemed by the Investigator; it also included events if causality was missing), and who discontinued from treatment due to a TEAE are presented.
A summary of serious and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.
|
Baseline through Week 56
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Mean Daily Opioid Dose at Weeks 49-52
Time Frame: Baseline, Weeks 49-52
|
Throughout the study, participants were asked to record changes in maintenance opioid consumption and use of opioid analgesics for breakthrough or exacerbation of pain in a paper diary.
Opioid consumption (including rescue opioids) of each participant was converted to an oral morphine-equivalent total daily dose (METDD).
Opioid consumption (in milligrams of METDD) was summarized in 4-week intervals.
The change from baseline to Weeks 49-52 is summarized.
|
Baseline, Weeks 49-52
|
Change From Baseline in Patient Assessment of Constipation-Quality of Life (PAC-QOL) Questionnaire at Week 52
Time Frame: Baseline, Week 52
|
The PAC-QOL questionnaire contains a total of 28 items, each rated within 4 subscales: physical discomfort, psychosocial discomfort, worries and concerns, and satisfaction.
Each item was rated on a 5-point Likert scale with the following score definitions, depending on the question: 0 = not at all (or none of the time), 1 = a little bit (or a little of the time), 2 = moderately (or some of the time), 3 = quite a bit (or most of the time), and 4 = extremely (or all of the time).
The total score is the mean of all non-missing items.
The range of the total score is 0 (response is 'not at all' for each item) to 4 (response is 'extremely' for each item).
Negative change from baseline values indicate improvement in constipation quality of life.
Each participant completed the PAC-QOL at Baseline and Week 52 using a 2-week recall period.
|
Baseline, Week 52
|
Change From Baseline in Patient-Reported Constipation Severity Assessment (PCSA) at Week 52
Time Frame: Baseline, Week 52
|
The PCSA asked participants to rate the severity of their overall constipation during the 24 hours prior to the assessment, using a scale of 0 to 10, where 0 is no constipation and 10 is the worst constipation imaginable.
|
Baseline, Week 52
|
Plasma Trough Concentrations of CB-5945
Time Frame: Weeks 4, 12, 24, 36, and 52
|
Blood samples for trough concentrations of CB-5945 were collected before the participant's morning dose of study drug at Weeks 4, 12, 24, 36, and 52.
Overall concentration was based on the mean trough level for each participant across all weeks.
|
Weeks 4, 12, 24, 36, and 52
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adjudicated Cardiovascular, Gastrointestinal, or Central Opioid Withdrawal Events
Time Frame: Baseline through Week 56
|
Cardiovascular (CV) events of interested included mycardial infarction, unstable angina, CV accident, congestive heart failure, serious arrhythmia, resuscitated cardiac arrest, and death. Gastrointestinal (GI) events of interest included emergency department visits for the serious adverse events of gastroenteritis, hepatitis, pancreatitis, nausea, vomiting, diarrhea, and abdominal pain or cramping. Central opioid withdrawal (OW) events of interest included opioid withdrawal syndrome. The adverse events that indicated central OW included, but were not limited to, hyperhidrosis, tremor, dysphoria, and myalgia. The number of participants with at least 1 confirmed CV, GI, or Central OW event is presented. |
Baseline through Week 56
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2402-006
- 5945-SOIC-12-05 (Other Identifier: Cubist Study Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid-Induced Constipation
-
Amsterdam UMC, location VUmcRadboud University Medical Center; University Medical Center Groningen; UMC Utrecht and other collaboratorsRecruitingConstipation, Opioid-InducedNetherlands
-
Kyowa Kirin Pharmaceutical Development LtdTerminatedOpioid Induced ConstipationNetherlands, United Kingdom
-
Valinor Pharma LLCActive, not recruiting
-
Theravance BiopharmaCompletedOpioid Induced ConstipationUnited States
-
St. John Health System, MichiganUnknownOpioid-induced ConstipationUnited States
-
ShionogiRecruitingOpioid-Induced Constipation (OIC)France
-
AstraZenecaCompletedOpioid-Induced Constipation (OIC)United States, Australia, Slovakia, Germany
-
AstraZenecaCompletedOpioid-Induced Constipation (OIC)United States
-
Bausch Health Americas, Inc.Wyeth is now a wholly owned subsidiary of PfizerCompletedOpioid-induced ConstipationUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Unknown
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States